Pfizer Loses 'Weige' Trademark Suit
This article was originally published in PharmAsia News
Executive Summary
China's Supreme Court has given its final decision that upholds the original verdict of the 'Weige' trademark infringement case, rejecting Pfizer's appeal and putting an end to the company's 11-year trademark battle against Guangzhou Welman Pharmaceutical (PharmAsia News, April 14, 2008). According to Welman officials, China has an erectile dysfunction drug market worth tens of billions of renminbi but the combined revenue of the three-largest imported ED brands did not exceed RMB 100 million last year. The firm believes the non-standardized market has missed the best window of opportunity and will not be making a breakthrough in the short term. Welman evaluated the 'Weige' trademark to be worth some RMB 700 million ($102.5 million) and it does not discount collaborations with MNCs. (Click here for more - Chinese Language)
You may also be interested in...
Intellectual Property Protection In China Improving In Incremental Stages - BioBusiness 2009 Conference
TAIPEI - China, generally thought to be a black hole for intellectual property, may be less dangerous for research-intensive pharmaceutical companies than is generally thought
Pfizer Loses Viagra Trademark Battle In China
Beijing Municipal Higher People's Court has rejected Pfizer's claims of trademark infringement and unfair competition against Guangzhou Welman Pharmaceutical and three other companies. The final verdict ended Pfizer's 10-year legal battle to secure the rights for Viagra's Chinese name "Weige" in China, trademarked by Welman in 1998. Welman says it has lost substantial marketshare in its erectile dysfunction drug over the past decade to counterfeit Viagra, which is the real rival. The firm does not dismiss the possibility of collaborating with Pfizer, including having joint use of the Weige trademark, to crack down on fake Viagra to reach a win-win situation. (Click here for more - Chinese Language)
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”